Biomaterial Database

A benefit-cost analysis of two-dose measles immunization in Canada. 1998

L Pelletier, and P Chung, and P Duclos, and P Manga, and J Scott

Division of Immunization, Laboratory Centre for Disease Control (LCDC), Ottawa, Canada.

In 1992, because of the limitations of the one-dose measles immunization program, the National Advisory Committee on Immunization (NACI) recommended a two-dose measles immunization program to eliminate measles. More recently, NACI recommended also a special catch-up program to prevent predicted measles outbreaks and to achieve an earlier elimination of measles. The objective of this study was to complete a benefit-cost analysis of a two-dose immunization program with and without a mass catch-up compaign compared with the current one-dose program. The resulting benefit: cost ratios vary between 2.61:1 and 4.31:1 depending on the strategy used and the age of the children targeted. Given the parameters established for this analysis, the benefits of a second-dose vaccination program against measles far outweight the costs of such a program under all scenarios.

UI	MeSH Term	Description	Entries
D007115	Immunization Schedule	Schedule giving optimum times usually for primary and/or secondary immunization.	Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D007223	Infant	A child between 1 and 23 months of age.	Infants
D008457	Measles	A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM.	Rubeola
D008458	Measles Vaccine	A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)	Vaccine, Measles
D009107	Mumps	An acute infectious disease caused by RUBULAVIRUS, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. (From Dorland, 28th ed)	Parotitis, Epidemic,Epidemic Parotitides,Epidemic Parotitis,Parotitides, Epidemic
D009108	Mumps Vaccine	Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.	Inactivated Mumps Vaccine,Inactivated Mumps Virus Vaccine,Live Attenuated Mumps Vaccine,Live Attenuated Mumps Virus Vaccine,Mumps Vaccine, Inactivated,Mumps Vaccine, Live Attenuated,Mumps Virus Vaccine, Inactivated,Mumps Virus Vaccine, Live Attenuated,Vaccine, Inactivated Mumps,Vaccine, Mumps
D002170	Canada	The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D002648	Child	A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL.	Children
D002675	Child, Preschool	A child between the ages of 2 and 5.	Children, Preschool,Preschool Child,Preschool Children
D003362	Cost-Benefit Analysis	A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes.	Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses